Our Posts

Metal-on-metal (MoM) hip implants, initially promoted as superior, have faced significant issues due to high failure rates and metal ion release. The DePuy ASR hip system, a notable example, was recalled in 2010 after 93,000 units were distributed globally. This recall highlighted the risks associated with MoM implants, leading to numerous lawsuits against Johnson & Johnson. Concerns over metal ion toxicity and device failures have prompted regulatory changes and increased scrutiny, impacting the reputation and financial standing of manufacturers involved.

The NIH has announced a plan to tackle the opioid crisis, highlighting the need for research in overdose reversal, addiction treatment, and pain management. The plan emphasizes developing new medications and technologies, including naloxone formulations and vaccines, to prevent opioid addiction and overdoses. The NIH stresses the importance of addressing chronic pain with non-addictive treatments to reduce opioid misuse. The initiative aims to leverage societal awareness to accelerate research and develop effective solutions to the opioid epidemic.

Parker Waichman LLP is assessing potential lawsuits against Drager Medical for injuries and deaths linked to Fabius Anesthesia Machines, which were recalled by the FDA as a Class I recall due to serious risks. The recall affects machines manufactured between June and November 2017, with 62 units distributed in the U.S. The recall was due to excess oil interfering with ventilation, posing a risk of failure during anesthesia. Parker Waichman LLP offers legal assistance to affected individuals seeking compensation for injuries caused by these machines.

Parker Waichman LLP is seeking financial compensation for individuals who have experienced amputations or adverse effects linked to the diabetes medication dapagliflozin, marketed as Farxiga and Xigduo XR by AstraZeneca. These SGLT2 inhibitors have been associated with serious health risks, including kidney damage, blood poisoning, and ketoacidosis. The law firm has a strong track record in securing compensation from pharmaceutical companies and urges affected individuals to act quickly due to varying state statutes of limitations. Parker Waichman LLP offers experienced legal representation for those impacted by these medications.

The FDA has issued a warning about Limbrel, a product by Primus Pharmaceuticals, due to reports of elevated liver function and acute hypersensitivity pneumonitis in users. These conditions are potentially life-threatening, prompting the FDA to advise users to stop taking Limbrel and consult their doctors. Although no serious injuries or deaths have been confirmed, the FDA has requested a recall of specific Limbrel doses. Parker Waichman LLP offers legal assistance to those affected by Limbrel's side effects.

A study in the Journal of the American Medical Association highlights the rising abuse of prescription opioids, despite a decrease in non-medical use from 2003 to 2013. Led by Dr. Beth Han, the research found an increase in use disorders and overdose deaths. The rate of use disorders rose from 0.6% to 0.9%, and overdose deaths increased from 4.5 to 7.8 per 100,000 people. The study emphasizes the need for effective prevention and intervention strategies, including the use of naloxone to reverse overdoses.

The fourth talcum powder ovarian cancer case against Johnson & Johnson is set to be tried in court, following three previous multimillion-dollar verdicts in 2016. Plaintiffs claim that using J&J's talcum powder products, like Baby Powder, caused ovarian cancer, citing studies linking talc to cancer. The plaintiff, a 56-year-old woman, used talcum powder for 36 years and developed ovarian cancer. J&J denies the allegations, maintaining no link between their products and cancer. Nearly 1,000 similar lawsuits are pending in St. Louis, with more cases consolidated in New Jersey and Los Angeles courts.

Women affected by conditions like Idiopathic Intracranial Hypertension and uterine perforation are filing lawsuits against Bayer Healthcare Pharmaceuticals, claiming inadequate warnings about Mirena IUD risks. Parker Waichman LLP represents these women, aiming to hold Bayer accountable and secure compensation for medical expenses, lost wages, and suffering. The firm has a successful track record against large corporations, recovering over $2 billion for clients. Affected users are encouraged to seek legal advice promptly due to time limitations on filing claims. Parker Waichman LLP offers expertise in navigating these complex lawsuits.

Parker Waichman LLP offers legal assistance for individuals seeking compensation for injuries related to Proton Pump Inhibitors (PPIs). They encourage affected individuals to file claims against PPI manufacturers to recover damages. Prompt action is advised to avoid losing legal rights. Interested parties can contact Parker Waichman LLP at 1-800-YOURLAWYER or fill out a free consultation form to discuss their rights and claim options with an experienced PPI lawyer.

Parker Waichman LLP is evaluating lawsuits against Medtronic for injuries caused by their cardiac defibrillators, which are subject to a Class I recall due to a manufacturing defect. This defect can prevent the devices from delivering necessary electrical shocks, posing severe risks to patients. The FDA has issued warning letters to Medtronic for unresolved defects. Affected individuals may be eligible for compensation. Parker Waichman LLP offers free consultations to discuss potential claims and has a history of securing significant compensation for clients.

The FDA has identified certain multi-use endoscope connectors as a source of cross-contamination in gastrointestinal endoscopy, posing a risk of severe infections. The FDA advises against using 24-hour multi-patient connectors, which lack backflow prevention and reprocessing features. The ERBEFLO port connector by Erbe USA Inc. was specifically mentioned. The FDA recommends using single-use connectors or reusable ones with backflow prevention that are properly reprocessed. Parker Waichman LLP is investigating cases related to infections from these procedures and offers free consultations for potential claims.

A large study suggests that proton pump inhibitors (PPIs), commonly used for heartburn, may increase the risk of early death. Researchers found a 25% higher risk of death in PPI users compared to those using H2 blockers. PPIs, available over-the-counter, are often used long-term despite recommendations for short-term use. The study highlights potential risks, including kidney disease, abnormal gut microbes, and increased risks of fractures, heart attacks, and dementia. Experts urge caution in prescribing PPIs, emphasizing the need for periodic medical reassessment.

In response to a surge in Xarelto bleeding lawsuits, Judge Eldon Fallon has extended the filing deadline by 90 days for inclusion in the multidistrict litigation in Louisiana. Janssen Pharmaceuticals faces numerous lawsuits alleging serious adverse events, including bleeding episodes and deaths. Initial bellwether trials are set for February 2017, with state-level trials in Pennsylvania scheduled for August 2017. Xarelto, unlike warfarin, lacks an antidote for bleeding, raising safety concerns. Plaintiffs claim Janssen's marketing emphasized convenience over safety, failing to warn about bleeding risks.

The first trial over allegations against Johnson & Johnson's DePuy Pinnacle hip devices has begun, focusing on claims of defective design leading to premature failures and metal debris entering patients' bloodstreams. The trial, overseen by U.S. District Judge Ed Kinkeade in Dallas, is a bellwether case among over 6,000 similar lawsuits. The plaintiff, a graphic artist, seeks damages for physical injuries, loss of earnings, and emotional distress. Johnson & Johnson previously recalled 93,000 ASR hip devices due to high failure rates, with concerns about cancer risks and genetic damage from metal-on-metal hips.

A lawsuit was filed on March 21, 2017, by 28 women against Bayer HealthCare, alleging that the company failed to warn them of serious health risks associated with the Essure birth control device. The case, initially in the Superior Court of Alameda County, seeks to be moved to federal court. Plaintiffs claim Essure caused complications like device migration, organ perforation, and chronic pain. Despite FDA approval in 2002, serious side effects emerged later, leading to a black box warning. The lawsuit accuses Bayer of misleading marketing and inadequate risk disclosure.

Parker Waichman LLP is a national plaintiffs' law firm specializing in maximizing financial compensation for clients affected by medical malpractice and defective products. They focus on cases involving ulcerative colitis patients who experienced severe side effects, such as sepsis and blood clotting, after taking corticosteroids before surgery. The firm emphasizes the importance of legal representation, noting that clients with attorneys typically receive higher settlements. They operate on a contingency fee basis, ensuring clients pay nothing upfront. With over $2 billion recovered for clients, Parker Waichman LLP is committed to achieving justice and substantial compensation for those harmed.

Regulators in the UK, EMA, and FDA have warned that Invokana (canagliflozin), a type 2 diabetes medication, may increase the risk of lower limb amputations. This risk is particularly noted in patients with poor diabetes control and cardiovascular issues. Healthcare professionals are advised to monitor patients for foot problems and consider discontinuing the drug if necessary. The FDA has added a boxed warning to Invokana and Invokamet labels. Legal consultations are available for those considering lawsuits related to Invokana's side effects.

ACE inhibitors, used to treat high blood pressure, have been linked to an increased risk of lung cancer. A study in the British Medical Journal found a 14% higher risk of lung cancer in ACE inhibitor users compared to those using angiotensin II receptor blockers, rising to 31% after 10 years. This risk may be due to the accumulation of bradykinin and substance P in the lungs. Common side effects of ACE inhibitors include rash, headache, and dry cough, with severe effects like angioedema and kidney failure. Parker Waichman, LLP is investigating potential lawsuits related to these findings.

Parker Waichman LLP discusses the ongoing lawsuits related to SGLT2 inhibitors, diabetes drugs linked to severe injuries like limb amputation and kidney damage. These drugs, including Invokana and Farxiga, have led to numerous lawsuits against manufacturers such as Johnson & Johnson and AstraZeneca. The cases are part of a Multi-district Litigation in New Jersey, with no settlements yet. Parker Waichman LLP, experienced in drug defect cases, offers legal representation to affected individuals, aiming to secure compensation for their injuries.

Parker Waichman LLP, a New York-based law firm, represents diabetes patients harmed by empagliflozin, a drug linked to severe side effects like amputations. Empagliflozin, marketed as Jardiance, is used for Type-2 diabetes but has been associated with increased amputation risks. The European Medical Association issued warnings about these risks, leading to mandatory label updates. Parker Waichman LLP offers experienced legal representation for those affected, emphasizing their success in pharmaceutical litigation and commitment to securing compensation without upfront costs.

Nearly 700 lawsuits have been filed in the Bair Hugger warming blanket multidistrict litigation (MDL) in Minnesota, alleging the system causes severe infections. The court requires plaintiffs to complete a "Plaintiff Fact Sheet" within 90 days. The Bair Hugger system, used to maintain body temperature during surgeries, allegedly leads to deep joint infections, necessitating additional surgeries or amputations. The MDL process consolidates cases for pretrial proceedings, aiming to streamline discovery and avoid inconsistent rulings. The system, approved by the FDA in 1988, has been used in over 200 million patients.

Medline Industries Inc., a Chicago-based medical supplier, faces lawsuits from 18 plaintiffs over counterfeit surgical mesh sold under the C. R. Bard/Davol brand. The mesh, used for hernia repairs, was actually made by a company in Delhi, India. The FDA warned about the mesh's sterility and performance issues, leading to a recall. Medline is named in eight lawsuits for selling "defective and unreasonably dangerous" mesh. Medline is suing Ram Medical and its insurer for legal expenses related to these lawsuits.

If you or a loved one experienced a heart attack, stroke, or other serious medical event after using Actemra, contact Parker Waichman LLP for legal assistance. Actemra was marketed as a safe treatment for rheumatoid arthritis, but may have serious risks. Prompt action is crucial to protect your rights. Call 1-800-YOURLAWYER (1-800-968-7529) or fill out the consultation form for a callback from an experienced lawyer to discuss your options.

3M is facing a lawsuit over its Bair Hugger surgical warming blanket, which allegedly caused burn injuries, unlike most claims that focus on infections. The Bair Hugger, used in over 80% of U.S. hospitals, maintains body temperature during surgery by pumping warm air into a blanket. The plaintiff claims the device is defectively designed, seeking compensation from 3M and Arizant Healthcare. Over 800 lawsuits have been filed, primarily alleging infections, with a multidistrict litigation established in Minnesota to handle these cases.